Can B Corp. Secures Ownership and Control of Two Cannabis Patents Valued at $122 Million and Potentially in Excess of $750 Million
March 11, 2024 08:15 ET
|
Can B Corp
The Patents Term – Presumed Valid By Law – Extends to 2035 HICKSVILLE, NY, March 11, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Can B Corp., a Florida corporation (OTCQB: CANB) (“Can B”), a...
New Notice of U.S. Patent Allowance Granted to Axim® Biotechnologies for Suppository Formulations Comprising Cannabinoids
November 21, 2019 09:00 ET
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today...
CURE Pharmaceutical Secures Patent on Oral Thin Film Containing Bioactive Cannabinoid Molecules
May 22, 2019 07:25 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the issuance of U.S. Patent No. 10,307,397,...
CURE Pharmaceutical Expands U.S. DEA Approval to Manufacture Pharmaceuticals Using Whole Cannabis Plant
March 12, 2019 07:25 ET
|
Cure Pharmaceutical Holding Corp.
OXNARD, Calif., March 12, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced it has broadened its U.S. Drug Enforcement...
CURE Pharmaceutical Secures Patent for Oral Thin Film Containing Bioactive Cannabinoid Molecules
September 25, 2018 08:45 ET
|
CURE Pharmaceutical
LOS ANGELES, Sept. 25, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, announced the allowance of an oral thin film patent (U.S. Patent...